INT57954

Context Info Confidence 0.11 First Reported 1993 Last Reported 2006 Negated 0 Speculated 0 Reported most in Abstract Documents 4 Total Number 5 Disease Relevance 4.51 Pain Relevance 0.89

plasma membrane (Anxa3) cytoplasm (Anxa3)

Anatomy Link Frequency plasma 1 VCS 1 heart 1 Anxa3 (Rattus norvegicus)

Pain Link Frequency Relevance Heat cva 7 95.00 Pain 4 91.60 Angina 4 83.80

Disease Link Frequency Relevance Heat Thrombosis 7 99.68 Congenital Anomalies 2 99.04 Obesity 1 98.78 Heart Disease 1 98.60 Neurological Disease 1 98.30 Malignant Neoplastic Disease 1 97.86 Disease 2 97.20 Pulmonary Embolism 7 95.00 Syndrome 6 94.88 Infarction 4 94.40

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

The patient had none of the following risk factors for pulmonary emboli: malignancy, neurological disease, heart disease, obesity, pregnancy, or a congenital coagulative abnormality such as deficiency of AT-III, protein C, protein S, or plasminogen.

Negative_regulation (deficiency) of AT-III in heart associated with malignant neoplastic disease, neurological disease, heart disease and obesity

1) Confidence 0.11 Published 1996 Journal Nihon Kyobu Shikkan Gakkai Zasshi Section Abstract Doc Link 8622276 Disease Relevance 1.02 Pain Relevance 0.27

The investigation of her family revealed that her son also showed decrease AT-III activity, indicating a congenital abnormality. 26 families with this disease have been reported in Japan.

Negative_regulation (decrease) of AT-III associated with congenital anomalies and disease

2) Confidence 0.10 Published 1993 Journal Kokyu To Junkan Section Abstract Doc Link 8235115 Disease Relevance 0.97 Pain Relevance 0.20

AT-III activity was found to be only 50% of normal value, indicating that the pulmonary thromboemboli were due to AT-III deficiency.

Negative_regulation (deficiency) of AT-III

3) Confidence 0.07 Published 1993 Journal Kokyu To Junkan Section Abstract Doc Link 8235115 Disease Relevance 0.85 Pain Relevance 0.25

Antithrombin III (AT-III), responsible for a large part of thrombin inactivation capacity in plasma, is the most powerful inhibitor of the thrombosis process.

Negative_regulation (inhibitor) of AT-III in plasma associated with thrombosis

4) Confidence 0.03 Published 2006 Journal Clin. Nephrol. Section Abstract Doc Link 16429847 Disease Relevance 0.86 Pain Relevance 0.08

At advanced examinations due to lack of response to heparin and clinical worsening, VCS and AT-III deficiency were determined.

Negative_regulation (deficiency) of AT-III in VCS

5) Confidence 0.03 Published 2006 Journal Clin. Nephrol. Section Abstract Doc Link 16429847 Disease Relevance 0.81 Pain Relevance 0.09

General Comments

This test has worked.